Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
43m
The vaccine is recommended for use only in the run-up to RSV season. It's time for RSV, flu, and COVID shots, and the CDC has ...
You may have been too young to remember, but depending on your state’s school immunization requirements, you likely received ...
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
Sanofi - Aventis Groupe said that the data featured at IDWeek from several national immunization programs will reinforce the proven ...
Respiratory virus season is arriving, once again, and the La Plata County Public Health Department is urging residents to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback